Fluconazole: adverse event reports filed with FDA

17,175

reports as suspect product

0.1% of all reports · about 764 a year

1,458

reports, 12 months to June 2026

1,528 in the 12 months before

90.7%

marked serious by the reporter

79% across the class

17.7%

record death among outcomes, as reported

3,038 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Fluconazole reports recording the termmedian drug in azole antifungal

1. Drug ineffectivethe medicine did not work as expected15.4%2,641
2. Drug interactionan interaction between medicines13.2%2,263
3. Off label useused for a purpose or in a way not on the label8.9%1,526
4. Pyrexiafever5.5%944
5. Headachehead pain5.5%937
6. Rashskin rash4.1%703
7. Hypersensitivityan allergic-type reaction3.8%647
8. Nauseafeeling sick3.7%639
9. Thrombocytopenialow platelets3.6%613
10. Painpain, site not specified3.5%602
11. Exposure during pregnancythe medicine was taken during pregnancy3.3%575
12. Condition aggravatedthe condition being treated got worse3.2%551
13. Erythemaskin redness3%511
14. Drug hypersensitivityan allergic-type reaction to a medicine2.9%501
15. Drug intolerancethe medicine was not tolerated2.9%498
16. Fatiguetiredness2.9%498
17. Diarrhoealoose or frequent stools2.8%484
18. Product use in unapproved indicationused for a purpose not on the label2.7%470
19. Acute kidney injurysudden loss of kidney function2.7%463
20. Hepatic enzyme increasedraised liver enzymes2.6%446
21. Hypertensionhigh blood pressure2.6%444
22. Rash erythematousa red rash2.6%441
23. Product use issuea problem in how the product was used2.5%436
24. Overdosea dose above the recommended amount2.5%432
25. Dyspnoeashortness of breath2.5%430
26. Treatment failurethe treatment did not work2.5%426
27. Infusion related reactiona reaction during or soon after an infusion2.5%425
28. Constipationconstipation2.4%417
29. Candida infectionthrush, a yeast infection2.4%404
30. Anaemialow red blood cells2.3%401

Top 30 of 2,134 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 16 drugs in the azole antifungal class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 69,035 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 29.4% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 17,175 reports.

Drugs most often listed in the same reports

Other products listed in reports where Fluconazole is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the azole antifungal class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Fluconazole as a suspect or interacting product; reports listing it only as a concomitant medication (39,970) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.